Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) said company executives will present business updates at two investor conferences in November 2025. Fireside chats are scheduled at the UBS Global Healthcare Conference on Nov 10, 2025 at 4:15 p.m. ET in Palm Beach Gardens, Florida, and at the Jefferies London Healthcare Conference on Nov 18, 2025 at 9:00 a.m. ET / 1:00 p.m. GMT. Investors can access live webcasts and archived recordings via Liquidia’s investor events page. Archived recordings will remain available for at least 30 days after each event.

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November:

• 2025 UBS Global Healthcare Conference on Monday, November 10 beginning at 4:15 p.m. ET in Palm Beach Gardens, Florida
• Jefferies London Healthcare Conference on Tuesday, November 18 beginning at 9:00 a.m. ET/1:00 p.m. GMT

Access to webcasts of both presentations will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations. Archived, recorded versions of the presentations will be available on Liquidia’s website for at least 30 days following the event.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com

FAQ

When will Liquidia (LQDA) present at the UBS Global Healthcare Conference in 2025?

Liquidia executives will present at the UBS Global Healthcare Conference on Nov 10, 2025 at 4:15 p.m. ET in Palm Beach Gardens, Florida.

What time is Liquidia's (LQDA) presentation at the Jefferies London Healthcare Conference on Nov 18, 2025?

The fireside chat is scheduled for Nov 18, 2025 at 9:00 a.m. ET / 1:00 p.m. GMT.

How can investors watch Liquidia (LQDA) presentations from the November 2025 conferences?

Live webcasts and archived recordings will be available on Liquidia’s investor events page at https://liquidia.com/investors/events-and-presentations.

For how long will Liquidia (LQDA) archive the conference presentation recordings?

Archived recordings will be available on the company website for at least 30 days after each event.

Will Liquidia (LQDA) executives provide business updates at the November 2025 conferences?

Yes, members of Liquidia’s executive leadership team will provide business updates during fireside chats at both November conferences.

Are the Liquidia (LQDA) conference webcasts open to the public or only to registered investors?

Access to the webcasts is available to investors and other interested parties via Liquidia’s investor events webpage.